• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Identification of deferasirox as a human xanthine oxidase inhibitor.

作者信息

Qi Yunfei, He Xinheng, Wu Xiaoshan, Zhou Tingting, Liang Ningning, Jiao Jiazheng, Chen Yanhao, Yuan Yue, Zhang Yuwei, Wang Yucheng, Liu Yan, Ding Qiurong

机构信息

CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.

CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 201203, China.

出版信息

Life Med. 2025 Mar 31;4(2):lnaf014. doi: 10.1093/lifemedi/lnaf014. eCollection 2025 Apr.

DOI:10.1093/lifemedi/lnaf014
PMID:40370485
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12075764/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d75/12075764/592c57b95b94/lnaf014_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d75/12075764/4ebf1d65e196/lnaf014_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d75/12075764/592c57b95b94/lnaf014_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d75/12075764/4ebf1d65e196/lnaf014_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d75/12075764/592c57b95b94/lnaf014_fig2.jpg

相似文献

1
Identification of deferasirox as a human xanthine oxidase inhibitor.地拉罗司作为一种人黄嘌呤氧化酶抑制剂的鉴定。
Life Med. 2025 Mar 31;4(2):lnaf014. doi: 10.1093/lifemedi/lnaf014. eCollection 2025 Apr.
2
Design, synthesis and biological evaluation of novel xanthine oxidase inhibitors bearing a 2-arylbenzo[b]furan scaffold.新型含 2-芳基苯并[b]呋喃骨架的黄嘌呤氧化酶抑制剂的设计、合成与生物评价。
Eur J Med Chem. 2018 May 10;151:849-860. doi: 10.1016/j.ejmech.2018.01.096. Epub 2018 Feb 2.
3
Quick identification of xanthine oxidase inhibitor and antioxidant from Erycibe obtusifolia by a drug discovery platform composed of multiple mass spectrometric platforms and thin-layer chromatography bioautography.通过由多个质谱平台和薄层色谱生物自显影组成的药物发现平台，快速鉴定毛钩藤中的黄嘌呤氧化酶抑制剂和抗氧化剂。
J Sep Sci. 2014 Aug;37(16):2253-9. doi: 10.1002/jssc.201400342. Epub 2014 Jun 30.
4
Inhibition of xanthine oxidase by 4-hydroxy-6-mercaptopyrazolo[3,4-d]pyrimidine.4-羟基-6-巯基吡唑并[3,4-d]嘧啶对黄嘌呤氧化酶的抑制作用。
Biochem Pharmacol. 1989 Dec 1;38(23):4315-20. doi: 10.1016/0006-2952(89)90531-5.
5
Identification of an N-hydroxyguanidine reducing activity of xanthine oxidase.黄嘌呤氧化酶的N-羟基胍还原活性的鉴定。
Eur J Biochem. 1998 Oct 1;257(1):178-84. doi: 10.1046/j.1432-1327.1998.2570178.x.
6
3,5,2',4'-Tetrahydroxychalcone, a new non-purine xanthine oxidase inhibitor.3,5,2',4'-四羟基查耳酮，一种新型非嘌呤黄嘌呤氧化酶抑制剂。
Chem Biol Interact. 2011 Feb 1;189(3):161-6. doi: 10.1016/j.cbi.2010.12.004. Epub 2010 Dec 15.
7
[Study on drug-target binding kinetics profiles of flavonoids in Chrysanthemum morifolium and xanthine oxidase].[菊花中黄酮类化合物与黄嘌呤氧化酶的药物靶点结合动力学特征研究]
Zhongguo Zhong Yao Za Zhi. 2021 Apr;46(7):1822-1831. doi: 10.19540/j.cnki.cjcmm.20201230.501.
8
X-ray crystal structure of a xanthine oxidase complex with the flavonoid inhibitor quercetin.黄嘌呤氧化酶与黄酮类抑制剂槲皮素复合物的 X 射线晶体结构。
J Nat Prod. 2014 Jul 25;77(7):1693-9. doi: 10.1021/np500320g. Epub 2014 Jul 1.
9
Inhibitory effects of xanthine oxidase inhibitor, topiroxostat, on development of neuropathy in db/db mice.黄嘌呤氧化酶抑制剂托匹司他对 db/db 小鼠神经病变发展的抑制作用。
Neurobiol Dis. 2021 Jul;155:105392. doi: 10.1016/j.nbd.2021.105392. Epub 2021 May 14.
10
2,6-Dichlorophenolindophenol is a competitive inhibitor for xanthine oxidase and is therefore not usable as an electron acceptor in the fluorometric assay.2,6-二氯酚靛酚是黄嘌呤氧化酶的竞争性抑制剂，因此在荧光测定中不能用作电子受体。
Free Radic Biol Med. 1992;12(3):189-92. doi: 10.1016/0891-5849(92)90026-d.

本文引用的文献

1
Optimized protocols for efficient gene editing in mouse hepatocytes using CRISPR-Cas9 technology.利用 CRISPR-Cas9 技术优化小鼠肝细胞中基因编辑的效率的方案。
STAR Protoc. 2021 Dec 23;3(1):101062. doi: 10.1016/j.xpro.2021.101062. eCollection 2022 Mar 18.
2
Xanthine oxidase inhibitors: patent landscape and clinical development (2015-2020).黄嘌呤氧化酶抑制剂：专利全景与临床开发（2015-2020 年）。
Expert Opin Ther Pat. 2020 Oct;30(10):769-780. doi: 10.1080/13543776.2020.1811233. Epub 2020 Sep 14.
3
Asymptomatic hyperuricaemia: a silent activator of the innate immune system.
无症状高尿酸血症：固有免疫系统的沉默激活剂。
Nat Rev Rheumatol. 2020 Feb;16(2):75-86. doi: 10.1038/s41584-019-0334-3. Epub 2019 Dec 10.
4
In Vitro Expansion of Primary Human Hepatocytes with Efficient Liver Repopulation Capacity.高效肝定植能力的原代人肝细胞的体外扩增。
Cell Stem Cell. 2018 Dec 6;23(6):806-819.e4. doi: 10.1016/j.stem.2018.10.018. Epub 2018 Nov 8.
5
A prospective study of tubular dysfunction in pediatric patients with Beta thalassemia major receiving deferasirox.一项关于接受地拉罗司治疗的重型β地中海贫血患儿肾小管功能障碍的前瞻性研究。
Pediatr Hematol Oncol. 2013 Nov;30(8):748-54. doi: 10.3109/08880018.2013.823470.
6
Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months.地拉罗司治疗 27 个月后导致重型β地中海贫血患者出现范可尼综合征。
Transfusion. 2011 May;51(5):949-54. doi: 10.1111/j.1537-2995.2010.02939.x. Epub 2010 Nov 15.
7
Acquired proximal renal tubular dysfunction in β-thalassemia patients treated with deferasirox.接受地拉罗司治疗的β地中海贫血患者获得性近端肾小管功能障碍。
J Pediatr Hematol Oncol. 2010 Oct;32(7):564-7. doi: 10.1097/MPH.0b013e3181ec0c38.
8
The role of the [2Fe-2s] cluster centers in xanthine oxidoreductase.[2Fe-2s]簇中心在黄嘌呤氧化还原酶中的作用。
J Inorg Biochem. 2000 Nov;82(1-4):43-9. doi: 10.1016/s0162-0134(00)00165-3.
9
Studies on milk xanthine oxidase. Some spectral and kinetic properties.牛奶黄嘌呤氧化酶的研究。一些光谱和动力学性质。
J Biol Chem. 1969 Apr 10;244(7):1682-91.